復宏漢霖-B(02696.HK)與諾靈生物達成抗體偶聯藥物共同開發戰略合作
復宏漢霖-B(02696.HK)公佈,與諾靈生物達成戰略合作,共同開發抗體偶聯藥物(antibody-drug conjugate, ADC)。根據協議,雙方將依託各自技術優勢,基於復宏漢霖自主研發的抗體和諾靈生物的新一代ADC技術平臺,融合互補,共同開發及評估多個創新型ADC候選藥物,加速推進候選藥物的研發及上市。
ADC藥物是在抗體的基礎上偶聯小分子細胞毒性藥物,具備了抗體的特異性和細胞毒性藥物的殺傷性,相較化療精準性更高、毒性更小,素有「魔法子彈」之稱。當ADC藥物進入體內後,首先與癌細胞表面的特異抗原結合,並通過細胞內吞作用使細胞毒性藥物發揮作用,幹擾癌細胞的複製和生長,致使癌細胞凋亡。當前全球有多款HER2、CD30、Trop-2等靶點ADC藥物上市,主要集中在實體瘤和血液腫瘤的後線治療,可顯着提高患者生存質量,開發前景廣闊。
復宏漢霖指,此次與諾靈的戰略合作,有助於公司將已有的蛋白技術與ADC技術結合,進一步鞏固和拓展在ADC領域的佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.